Protaryx Medical Announces $8.3M in Funding for First-in-Class Technology for Left Atrial Access in Transcatheter Cardiac Procedures

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Protaryx„¢ Medical, a company committed to reimagining access to the left atrium for transcatheter cardiac procedures, today announced that it has raised $8.3 million in funding to develop the companys first-in-class device for precision transseptal access to the left atrium during structural heart and catheter ablation procedures. The companys funding includes non-dilutive grants and a seed round totaling $3.2 million and the recently closed $5.1M Series A financing led by Ajax Health, with participation from University of Maryland (UM) Ventures, a returning investor.

Designed for use in catheter-based procedures such as mitral valve repair and replacement, left atrial appendage closure and catheter ablation to treat cardiac arrhythmias, the Protaryx device is intended to provide physicians with confidence in accuracy and safety through independent steerability and three-dimensional control to streamline rapid crossing to the left heart.

There is currently an opportunity for technologies that can optimize access to the left atrium during beating-heart cardiology procedures, a market that continues to see worldwide growth, said Terri Burke, chief executive officer and co-founder of Protaryx. Were pleased to partner with the experienced team at Ajax Health to leverage its proven expertise and reputation for supporting successful emerging medical device companies.

Transseptal access performed with todays existing technology can be challenging, time-consuming and difficult to learn, which creates a clear pain point for physicians, said Protaryx co-founder James S. Gammie, M.D., professor and chief of Cardiac Surgery at the University of Maryland School of Medicine as well as the co-founder and inventor for Harpoon Medical, which was acquired by Edwards Lifesciences in 2017. The innovative Protaryx device is designed with the goal of simplifying transseptal access for physicians, which may lead to fewer complications and improved outcomes for patients.

In addition to the investment, Ajax Health leaders Doug Koo, chief financial officer and managing director, and Aftab Kherani, chief medical officer and managing director, will join the Protaryx Board of Directors.

We are pleased to include Protaryx in the Ajax portfolio, and I’m personally excited to join the board to move this innovative company forward, said Koo. We have been impressed with the team and the potential of this unique technology to fill a growing clinical need in cardiovascular care.

The Protaryx device is not available for sale anywhere in the world.

About Protaryx Medical

Protaryx Medical is a medical device company committed to reimagining access to the left atrium for transcatheter cardiac procedures. Taking an innovative approach, Protaryx aims to deliver meaningful improvements for physicians and patients. The company is headquartered in Baltimore, Maryland, with engineering operations in Minneapolis, Minnesota. Learn more at

About Ajax Health

Ajax Health seeks to identify, support and scale disruptive technologies in the healthcare space. Taking an active operating role, the Ajax team has a proven track record of helping companies of all sizes, stages and structures achieve their value-creation goals. Ajax is headquartered in Menlo Park, California and backed by an investor group led by HealthQuest Capital.

About UM Ventures

UM Ventures commercializes the University of Maryland, Baltimores (UMB) breakthrough therapies, diagnostics, and devices. Through early-stage investment in innovative technologies with promising commercial potential and strong management teams, UM Ventures fuels the creation of UMB start-up companies. Since the program began in 2014, UM Ventures has made 12 investments in nine companies, four of whichHarpoon Medical, Living Pharma, SurgiGyn, and Breethehave been acquired. Learn more about the UM Ventures investment portfolio at

For Protaryx:


Hannah Boxerman

[email protected]

(707) 326-0870